1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Neoplasm Metastasis in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bodei, L; Gönen, M; Krebs, S; Lewis, JS; Lohrmann, C; Lyashchenko, SK; O'Donoghue, JA; Pandit-Taskar, N; Raj, N; Reidy-Lagunes, D; Staton, KD; Weber, WA | 1 |
| Akhurst, TJ; Beylergil, V; Carrasquillo, JA; Hudis, CA; Larson, SM; Lu, Y; Lyashchenko, SK; Modi, S; Morris, PG; O'Donoghue, J; Smith-Jones, PM; Solit, D | 1 |
| Bal, A; Bhusari, P; Dhawan, DK; Mittal, BR; Parmar, M; Shukla, J; Singh, G; Vatsa, R | 1 |
| Gershman, BM; Guo, H; Miao, Y; Shenoy, N; Sklar, LA; Yang, J | 1 |
| Calame-Christe, M; Eberle, AN; Froidevaux, S; Sumanovski, L; Tanner, H | 1 |
| Chu, DZ; Leong, L; Liu, A; Raubitschek, AA; Shively, JE; Wilczynski, S; Williams, LE; Wong, JY; Wu, AM; Yamauchi, DM; Yazaki, PJ; Zhan, J | 1 |
| Baum, RP; Müller, D; Senftleben, S; Wehrmann, C; Zachert, C | 1 |
| Bruchertseifer, F; Huber, T; Kessler, H; Knör, S; Magdolen, V; Morgenstern, A; Sato, S; Schmitt, M; Seidl, C; Senekowitsch-Schmidtke, R | 1 |
| Cutler, CS; Deutsch, E; Ehrhardt, GJ; Jurisson, SS; Smith, CJ; Tyler, TT | 1 |
1 review(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Neoplasm Metastasis
| Article | Year |
|---|---|
Current and potential therapeutic uses of lanthanide radioisotopes.
Topics: Alpha Particles; Beta Particles; Chelating Agents; Heterocyclic Compounds, 1-Ring; Humans; Metals, Rare Earth; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Peptide Fragments; Radioisotopes; Radionuclide Imaging; Receptors, Somatostatin; Technetium | 2000 |
3 trial(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Neoplasm Metastasis
| Article | Year |
|---|---|
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist
Topics: Adult; Aged; Chelating Agents; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Prognosis; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Young Adult | 2019 |
Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Feasibility Studies; Female; Genes, erbB-2; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Lutetium; Mastectomy; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Proteins; Pilot Projects; Radioimmunotherapy; Radioisotopes; Receptor, ErbB-2; Single Photon Emission Computed Tomography Computed Tomography; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tamoxifen; Tissue Distribution; Trastuzumab | 2017 |
A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal; Carcinoembryonic Antigen; Female; Heterocyclic Compounds, 1-Ring; Humans; Immunoglobulin G; Immunotoxins; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Radioimmunotherapy; Yttrium Radioisotopes | 2006 |
5 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Neoplasm Metastasis
| Article | Year |
|---|---|
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Feasibility Studies; Female; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Pilot Projects; Positron-Emission Tomography; Radiometry; Safety; Tomography, X-Ray Computed; Trastuzumab | 2013 |
Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide.
Topics: alpha-MSH; Amino Acid Sequence; Animals; Binding, Competitive; Cell Line, Tumor; Feasibility Studies; Fluorodeoxyglucose F18; Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Lactams; Melanoma; Mice; Neoplasm Metastasis; Neoplasm Staging; Peptides, Cyclic; Reproducibility of Results; Staining and Labeling; Time Factors; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2009 |
DOTA alpha-melanocyte-stimulating hormone analogues for imaging metastatic melanoma lesions.
Topics: alpha-MSH; Animals; Chelating Agents; Diagnostic Imaging; Heterocyclic Compounds, 1-Ring; Melanoma, Experimental; Mice; Neoplasm Metastasis; Radiopharmaceuticals; Tissue Distribution | 2003 |
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
Topics: Adult; Aged; Bone Neoplasms; Female; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radioisotopes; Radiotherapy; Radiotherapy Dosage; Receptors, Peptide; Tomography, X-Ray Computed | 2007 |
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Topics: Alpha Particles; Animals; Bismuth; Cell Line, Tumor; Dimerization; Drug Discovery; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Ligands; Mice; Neoplasm Metastasis; Ovarian Neoplasms; Peptides; Polygeline; Radioisotopes; Receptors, Urokinase Plasminogen Activator; Solubility; Substrate Specificity; Tissue Distribution | 2008 |